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Background: The role of β-adrenergic stimulation on viral myocarditis has been investigated in animal models of
viral myocarditis. Excess stimulation of β-adrenergic receptors by catecholamines causes phosphorylation/activation
of cAMP response element binding protein (CREB) by the cAMP signaling pathway. CREB as an important regulator
of gene expression mediates the cardiovascular remodeling process and promotes anti-inflammatory immune
responses. However, the CREB expression and phosphorylation have not been studied, and the effects of carvedilol
(a nonselective β-adrenoceptor antagonist) on the CREB has not been investigated in the setting of acute viral
myocarditis.
Methods: This study was therefore designed to examine the effects of carvedilol on the transcriptional factor CREB
in a murine model of acute viral myocarditis. In a coxsackievirus B3 murine myocarditis model (Balb/c), effects of
carvedilol on plasma noradrenaline, heart rate and blood pressure, myocardial histopathological changes and
fibrosis, cardiomyocyte apoptosis, cardiac CREB and phosphorylated CREB, cytokine levels, and viral RNA were
studied.
Results: The expression and phosphorylation of CREB were decreased with concomitant increase of IL-6 and TNF-α
in murine coxsackievirus-induced acute viral myocarditis. The levels of IL-6 and TNF-α were correlated with the
expression of CREB or phosphorylated CREB. Carvedilol increased the cardiac CREB expression and phosphorylation
and decreased the plasma catecholamine levels and the production of IL-6 and TNF-α with amelioration of acute
viral myocarditis.
Conclusion: These results show that CREB may be involved in the pathophysiology of viral myocarditis and
carvedilol exerts some of its beneficial effects by increasing the CREB expression and phosphorylation.
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Viral myocarditis is a frequent cause of cardiac failure, es-
pecially in young adults [1]. Acute inflammation of the
heart appears to be a major cause of sudden, unexpected
death in persons younger than 40 years old [2] and often
follows viral infection [3]. Enteroviruses, particularly the
coxsackievirus B3 (CVB3), have been identified as the* Correspondence: liyuechun1980@sina.com
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reproduction in any medium, provided the orpredominant cause of viral myocarditis in both animal
models and humans [4]. Despite the well-characterized
molecular structure of coxsackieviruses [5] and the suc-
cessful use of common [6] or novel immunization proce-
dures [7-9] in animal models, immune suppression trials
[10] to reverse underlying active myocardial inflammation
have been largely disappointing, and no specific treatment
for viral myocarditis are in clinical use today. Therefore,
elucidation of the fundamental mechanisms involved in
the development of myocarditis, and the progression from
virus infection to heart failure is important.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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norepinephrine levels were elevated. Excess stimulation of
the β-adrenergic receptor by catecholamines may contrib-
ute to the pathogenesis of congestive heart failure of vari-
ous causes [11]. The cardiac responsiveness to β-adrenergic
stimulation in heart failure is associated with gene expres-
sion alterations in myocardial regulatory proteins which
are involved in the cAMP-dependent signal transduction
[12-15]. The transcriptional control by the cAMP-response
element binding protein (CREB) is a major mechanism
regulating the gene expression by the cAMP-dependent
signaling pathway [16-20]. CREB plays an important role in
the regulation of a number of genes involved in the main-
tenance of normal cellular function [16-20]. Several studies
suggested CREB as an important regulator of gene ex-
pression involved in the pathophysiology of heart failure
[21-24]. Transgenic mice with cardiac myocyte-specific
expression of dominant negative CREB showed impaired
contractile response to isoproterenol stimulation as well as
dilatation of the 4 chambers of the heart, mimicking idio-
pathic dilated cardiomyopathy [21]. Moreover, evidence
from an increasing number of studies has shown that
CREB mediates the cardiovascular remodeling process [25],
including inflammation [26], cell migration [27], and apop-
tosis [28,29]. However, CREB in viral myocarditis has not
been studied. The role of β-adrenergic stimulation on viral
myocarditis has also been investigated in animal models of
viral myocarditis. We and other investigators have recently
reported that the circulating plasma levels of cate-
cholamines were significantly increased in murine viral
myocarditis [30,31]. These results implicated that the
transcriptional factor CREB may be also involved in
the pathophysiology of viral myocarditis. Therefore, in the
present study, we examined the role of the transcriptional
factor CREB in murine coxsackievirus-induced acute viral
myocarditis.
Carvedilol, a third-generation, nonselective β-adrenoceptor
antagonist that also possesses α1-adrenergic blocking, anti-
oxidant, antiapoptotic, anti-inflammatory, and antifibrotic
properties, has been shown to provide greater benefit than
traditional β-adrenoceptor antagonists in chronic heart
failure [32]. Recently, our and other studies have demon-
strated protective effects of carvedilol in viral myocarditis
[30,31,33-35]. The beneficial action of carvedilol in murine
viral myocarditis may be at least partly due to its effects
of catecholamine reduction [30,31,33-35]. In patients
with heart failure, the reducion of catecholamines by β-
blockade “restored” the changes of the cardiac regulatory
proteins which are involved in the cAMP-dependent sig-
nal transduction [32,36,37]. Therefore, β-adrenoceptor an-
tagonists may also be useful to “normalize” the altered
CREB expression in viral myocarditis. However, its effects
on the CREB in experimental viral myocarditis has not yet
been investigated. Thus, in the present study, we studiedthe effects of carvedilol on the transcriptional factor CREB




The investigation conformed with the Guide for the Care
and Use of Laboratory Animals published by the US Na-
tional Institutes of Health (NIH Publication, 8th Edition,
2011), and all experiments were carried out in accordance
with China Animal Welfare Legislation and were approved
by the Wenzhou Medical College Committee on Ethics in
the Care and Use of Laboratory Animals. For the survival
study, individual mice were monitored daily and were
euthanized when they displayed signs of myocarditis-
associated morbidity such as excessive weakness and leth-
argy. All animals were anaesthetized with pentobarbital
(100 mg/kg, one dose intraperitoneally) prior to sacrifice.
Efficient anaesthesia was monitored through pinching the
hind paw, when sufficiently sedated the mice were eutha-
nized through cervical dislocation.
Mouse model of viral myocarditis
Specific pathogen-free inbred, 4-week-old, male Balb/c
mice, obtained from Shanghai Laboratory Animal Center,
China, were inoculated intraperitoneally with 1.0 × 106
plaque-forming units (pfu) of CVB3 (strain Nancy, ATCC
VR-30) diluted in phosphate-buffered saline (PBS) to a
final volume of 0.1 ml (n = 60). Group control was inocu-
lated intraperitoneally 0.1 ml with normal saline solution
(n = 30). The day of virus inoculation was defined as day 0.
Drug administration
Carvedilol was obtained from Roche China Co. (Shanghai,
China). Starting 24 h after infection carvedilol (10 mg/kg
per day, n = 30) were administered by gavage for 14 con-
secutive days, whereas normal control group (n = 30) and
myocarditis group mice (n = 30) received the normal sa-
line solution in the same way. Eight surviving mice from
each group were killed on day 7 or 14.
Plasma noradrenaline
Plasma noradrenaline was measured using high-perfor
mance liquid chromatography and electrochemical de-
tection. After mice were anesthetized intraperitoneally
with pentobarbital (50 mg/kg), the arterial blood samples
were taken and centrifuged at 3000 g for 15 min. The
plasma were stored at −80°C for subsequent determin-
ation of noradrenaline concentration. The experiment
was repeated 6 times for each sample.
Hemodynamic measurements
HR and blood pressure (BP) were measured using a
photoelectric tail cuff detection system (softron BP-98A
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for 10 minutes at 37°C in a thermostatically controlled
heating cabinet. The values were averaged from at least
three consecutive readings on each occasion.
Survival rate
Survival was measured over a 14-day period.
Myocardial histopathology
The ratio of heart weight to body weight (HW/BW) was
calculated. The heart tissue was fixed in 10% formalin,
embedded in paraffin, sectioned, and stained with
hematoxylin and eosin. Several sections of each heart
were scored blindly by two observers. The scores
assigned to these specific sections were averaged. The
extent of cellular infiltration and myocardial necrosis
was graded and scored as follows: 0 = no lesion; 1 + =
lesions involving <25% of the myocardium; 2 + = lesions
involving 25% to 50%; 3 + = lesions involving 50 to 75%;
and 4 + = lesions involving 75% to 100%.
Masson trichrome staining
The heart tissue specimen was cut in a 5-mm-thick,
fixed in 10% formalin, dehydrated and embedded in par-
affin. The slices were stained with Masson’s trichrome
stain (GENMED SCIENTIFICS INC. USA). Five visual
fields were randomly selected in each slice stained with
Masson’s trichrome under a microscope and measured
by Image Pro Plus image analysis software. Collagen vol-
ume fraction (CVF) obtained from the average ratio of
collagen area to total tissue area was used to evaluate
the extent of interstitial fibrosis. CVF excluded scars and
perivascular collagen areas.
Detection of apoptosis
Apoptosis was detected in myocardial tissue sections using
the terminal transferase-mediated DNA nick end labelling
(TUNEL) assay. Apoptotic cells were identified using an in
situ cell death detection kit, pod (Roche, Switzerland). The
paraffin sections of myocardial tissue (3 μm-thickness)
were deparaffinized for 5 min in xylone twice, and then
rehydrated in a series of serially diluted ethanol solutions
(100%, 95%, 90%, 80%, 70%, and then H2O). Tissue sec-
tions were then treated with proteinase K (final concentra-
tion of 20 ug/ml in 10 mM Tris–HCl, pH 7.4–7.8) for
30 min at 22°C. A positive control was prepared by incu-
bating a tissue section with DNase I (1 U/ml in 50 mM
Tris–HCl, pH7.5, 1 mg/ml BSA) for 10 min before protein-
ase K treatment. The paraffin sections incubated with 50 μl
TUNEL reaction mixture containing terminal deoxynu-
cleotidyl transferase (TdT) for 60 minutes at 37°C in a hu-
midified chamber in the dark. A negative control was
prepared without TUNEL enzyme. Tissue sections were
washed three times with PBS and the TUNEL-positiveapoptotic cardiomyocyte nuclei were examined under a
fluorescence microscope using an excitation wavelength in
the range of 450–550 nm and a detection wavelength in
the range of 515–565 nm. Tissue sections were then
treated with converter-POD in a humidified chamber for
30 min at 37 μ. and incubated with 50 ul DAB for 10 min.
Positive staining cells were manually counted in 10 ran-
domly selected fields of each slide by microscope (200×
magnification field). Cell death was expressed as the aver-
age percentage of total cells counted.
Assay of myocardial virus concentration
For the infectivity assay, portions of the heart were weighed
and homogenized aseptically in 2 mL PBS. After a 15-
minute centrifugation at 1500 g, virus titers in the super-
natants were determined by a plaque assay method, as
previously described [38]. In brief, VERO (African green
monkey kidney) cells suspended (1 × 106/mL) in Eagle’s
minimal essential medium (EMEM) with 5% FCS plus
100 μg/mL each penicillin and streptomycin were placed in
six-well plates and allowed to grow for 2 or 3 days at 37°C
in 5% CO2. After adsorption, the cells were overlaid with
3 mL EMEM containing 5% FCS and 1% methylcellulose.
After a 2-day incubation at 37°C in a humidified atmosphere
containing 5% CO2, the cells were fixed with acetic acid
and methanol (1:3) and stained with 1% crystal violet; pla-
ques were then counted with an inverted microscope. The
myocardial virus titer was expressed as log pfu/mg of heart.
Western blot analysis for CREB and phosphorylated CREB
Heart tissues were homogenized and dissolved with RIPA
buffer [150 mM NaCl, 1% Triton X-100, 1% sodium deoxy-
cholate, 0.1% SDS, 50 mM Tris (pH 7.4)] containing 1 M
PMSF (Phenylmethanesulfonyl fluoride). Protein concentra-
tions were determined with the BCA Protein Assay Kit.
Total protein (50 ug per lane) was separated on 12% SDS-
PAGE (sodium dodecyl sulfate polyacrylamide gel electro-
phoresis) and transferred to a PVDF membrane (BioRad,
Hercules, CA). Membranes were incubated with primary
antibodies according to the manufacturer’s protocol, subse-
quently washed with PBS-T (phosphate-buffered saline
Tween-20), and were incubated with an appropriate sec-
ondary antibody dependent to primary antibody. Results
were scanned and quantified using densitometry and Ima-
geQuant software and normalized to the housekeeping pro-
tein GAPDH. Phosphorylated CREB (pCREB), CREB and
GAPDH antibodies were obtained from Cell Signaling
Technology (Danvers, MA, USA). The experiment was re-
peated 3 times for each sample.
Total RNA extraction and reverse transcriptase-
polymerase chain reaction (RT-PCR)
Total RNA, frozen in liquid nitrogen, was extracted from
the myocardial samples by the Trizol method (Invitrogen,
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structions. cDNA was synthesized by reverse transcription
using total RNA (3 μg) as a template. Semiquantitative RT-
PCR was used to detect the mRNA abundance of interleu-
kin (IL)-6, tumor necrosis factor (TNF)-α, and monocyte
chemoattractant protein-1 (MCP-1) (Table 1). Additionally,
RT-PCR was also used to detect the CVB3 RNA abundance
in the infected myocardium. The mRNA abundance was
quantified as optical densities (OD) equalized with β-actin
mRNA levels using a BandScan 5.0 software (Glyko,
Novato, CA, USA). Nucleicacid sequences of all PCR prod-
ucts were confirmed to be identical to published GenBank
data. The experiment was repeated 3 times for each sample.Fluorescent quantitative real-time PCR
Total RNA, frozen in liquid nitrogen, was extracted from
the myocardial samples by the Trizol method (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s in-
structions. RNA concentration were quantified using the
spectrophotometer. cDNA was synthesized by reverse tran-
scription using total RNA (2 μg) as a template. The internal
control gene used was GAPDH. For PCR amplification, the
following mouse-specific sense and antisense primers were
used: IL-6, 5′- TGCCTTCTTGGGACTGAT-3′ (forward)
and 5′- TAAGCCTCCGACTTGTGA-3′ (reverse); TNF-а,
5′- CCACGCTCTTCTGTCTACTGA-3′ (forward) and
5′- AAGGTACAACCCATCGGCTG-3′ (reverse); GAPDH,
5′-AGGGAAATCGTGCGTGACAT-3′ (forward) and 5′-
CATCTGCTGGAAGGTGGACA-3′ (reverse). PCR amp-
lification was performed on a Light Cycler FastStart DNA
Master SYBR Green I. The amplification was performed
in a Roche Light Cycler 480 instrument under the following
condition: initial denaturation at 95°C for 5 minutes,
50 cycles of amplification at 95°C for 10 seconds, an-
nealing at 60°C for 10 seconds, and then extension at






CVB3 F-CGGTACCTTTGTGCGCCTGT 61 30 314
R-CAGGCCGCCAACGCAGCC
IL-6 F- TGCTGGTGACAACCACGGCC 60 33 308
R- GTACTCCAGAAGACCAGAGG
TNF-α F-CCTGTAGCCCACGTCGTAGC 50 31 374
R-TTGACCTCAGCGCTGAGTTG
MCP-1 F-GCCAACTCTCACTGAAGCC 50 30 161
R-GCTGGTGAATGAGTAGCAGC
β-actin F-AGGGAAATCGTGCGTGACAT 55 24 450
R-CATCTGCTGGAAGGTGGACAEnzyme-linked immunosorbent assay for cytokines in
the heart
Cytokine levels were measured with various enzyme-
linked immunosorbent assay (ELISA) kits manufactured
by Westang Biotech Co Ltd (Shanghai, China) for IL-6,
TNF-α, and MCP-1. The sensitivity of the kit is 16 pg/ml
for IL-6, 13 pg/ml for TNF-α, and 8 pg/ml for MCP-1.
Cytokine levels are expressed as pg/mg of heart. The ex-
periment was repeated 3 times for each sample.
Statistical analysis
All values were expressed as mean value ± standard error
(SE). Survival rate was analyzed by the Kaplan-Meier
method. The continuous variables were compared with a
Student’s t-test for two groups and with one way analysis
of variance (ANOVA) for >2 groups. Bivariate correla-
tions were performed by Pearson’s correlation. A value
of P < 0.05 was considered significant.
Results
Plasma noradrenaline levels
Plasma noradrenaline levels were significantly higher in
the carvedilol and myocarditis groups than in the nor-
mal control group on days 7 and 14 (Figure 1). However
carvedilol treatment notably decreased the plasma levels
of noradrenaline compared to the myocarditis group on
days 7 and 14 (Figure 1).
Hemodynamics of mice
HRs in the carvedilol group were significantly decreased
compared with the normal and myocarditis groups on days
7 and 14 (Figure 2a). Systolic blood pressure (SBP) in the
carvedilol group and myocarditis group were significantly
decreased compared with the normal group on days 7 and
14 (Figure 2b). No differences in SBP and diastolic bloodFigure 1 The effects of carvedilol on plasma noradrenaline on
days 7 and 14 (n = 8 in each group). Control, normal mice treated
with normal saline solution; Myocarditis, infected mice treated with
normal saline solution; Carvedilol, infected mice treated with carvedilol.
*P < 0.05 versus control; **P < 0.05 versus myocarditis.
Figure 2 The effects of carvedilol on heart rate and blood
pressure on days 7 and 14 (n = 8 in each group). a, heart rate;
b, systolic blood pressure; c, diastolic blood pressure.▲, Control;
◆myocarditis; ●carvedilol treatment. Control, normal mice treated
with normal saline solution; Myocarditis, infected mice treated with
normal saline solution; Carvedilol, infected mice treated with
carvedilol. *P<0.05 versus control; §P<0.05 versus myocarditis.
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myocarditis groups on days 7 and 14 (Figure 2c).
Survival rate
The survival rate of the uninfected mice (control group)
on day 14 were 100% (Figure 3a). The survival rate in
CVB3-inoculated mice followed for 14 days was 53.1%
for those treated with saline and 73.0% for those treated
with carvedilol (Figure 3a). The survival rate was signifi-
cantly increased in the carvedilol group compared to the
myocarditis group (P < 0.05).
HW/BW ratio
Seven and 14 days after infection, the myocarditis group
showed a reduction in BW and HW and an increase in
HW/BW ratio. The HW/BW ratio was significantly lower
in the carvedilol group than in the myocarditis group on
days 7 and 14 (Figure 3b).
Myocardial histopathology and fibrosis
On days 7 and 14 at sacrifice, severe injuries to myocar-
dium with cellular infiltration in the myocarditis group
were observed. The cardiac pathological scores, includ-
ing infiltration, necrosis, and myocardial CVF, were all
significantly decreased in the carvedilol group compared
with the myocarditis group (Figure 3c,d,e), indicating a
significantly reduced severity of disease. Representative
hematoxylin-eosin and Masson’s trichrome stained hearts
are shown in Figure 4.
Cardiomyocyte apoptosis
The TUNEL positive cells in the myocardium of the in-
fected mice were significantly increased compared with the
normal mice. Carvedilol treatment attenuated the increase
in percentages of apoptosis significantly (P < 0.05) com-
pared with the myocarditis group on days 7 (5.43 ± 1.22%
vs 7.29 ± 1.93%) and 14 (1.91 ± 0.72% vs 3.49 ± 1.40%).
The TUNEL positive cell nuclei appeared condensed and
rounded, showing typical features of apoptotic morphology
(Figure 5).
Virus titer of the heart
Virus titers of hearts in the infected mice were slightly
lower in the carvedilol group than in the myocarditis
group on days 7 and 14, but this effect did not reach
statistical significance (p > 0.05, Figure 6).
Figure 3 Effects of carvedilol on viral myocarditis. a: The survival rate in CVB3-inoculated mice followed for 14 days (n = 30 in each group).
Carvedilol significantly increased the survival rate in CVB3 infected mice compared to the myocarditis group (P < 0.05). b: HW/BW ratio (n = 8 in
each group); c: Histopathological score of cellular infiltration (n = 8 in each group); d: Histopathological score of myocardial necrosis (n = 8 in
each group); e: Total cardiac collagen volume fraction on day 14 (n = 8 in each group). ND, not detected. Control, normal mice treated with
normal saline solution; Myocarditis, infected mice treated with normal saline solution; Carvedilol, infected mice treated with carvedilol.
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CVB3-RNA abundance by semiquantitative RT-PCR-
analysis were found in the myocardium of the infectedmice on days 7 and 14. Carvedilol treatment produced
a slightly lower CVB3-RNA abundance in the infected
myocardium compared to the myocarditis group on day
Figure 4 Histopathology (Hematoxylin Eosin × 200) and fibrosis (Trichrome × 200) in the heart. (a) Histopathology in a normal group
(grade 0). (b) Representative histopathology in a myocarditis group. Several large foci of cellular infiltrations (arrow) in the inflammatory region
are shown (grade 3). (c) Representative histopathology in a carvedilol group. Several small foci of cellular infiltrations in the inflammatory region
(arrow) are shown (grade 2). (d) Representative Masson’s trichrome stained heart in a normal group. (e) Representative Masson’s trichrome
stained heart in a myocarditis group. (f) Representative Masson’s trichrome stained heart in a carvedilol group.
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(Figure 7). There were no significant differences in the
CVB3-RNA abundance between the carvedilol group
and myocarditis group on day 14.
Protein assay of CREB and pCREB
In the myocardium of the infected mice western blot
analysis revealed a significant decrease in the levels of
CREB and pCREB compared to the uninfected animals
on days 7 and 14 (Figure 8). On day 7, the levels of
CREB in the carvedilol group were significantly in-
creased compared with the myocarditis group, but the
levels of pCREB of the carvedilol group did not differ
compared with the myocarditis group (Figure 8). On day
14, the levels of CREB and pCREB in the carvedilolgroup significantly increased compared to the myocardi-
tis group (Figure 8).
Gene expression of cytokines by Semi-Quantitative PCR
analysis in the heart
On day 7, the mRNA levels of the IL-6, TNF-α, and MCP-
1 in the myocardium of the infected mice were significantly
upregulated compared with the normal group (Figure 9).
On day 7, the mRNA levels of the IL-6 and TNF-α were
significantly lesser in the carvedilol group compared with
the myocarditis group (P < 0.05; Figure 9a), but carvedilol
had no effect on the MCP-1. On day 14, no differences in
the mRNA levels of the IL-6, TNF-α, and MCP-1 were
found among the carvedilol group and myocarditis group
and normal control group (P > 0.05; Figure 9b).
Figure 5 Detection of apoptotic cardiomyocytes with the TUNEL assay (n = 8 in each group). Nuclei with brown staining indicated TUNEL
positive cells, which were indicated by a small white arrow. (a) normal group. (b) myocarditis group. (c) carvedilol group.
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in the heart
On day 7, the mRNA levels of the IL-6 and TNF-α in
the myocarditis group were significantly upregulated
compared with the normal group (Figure 10). On day 7,Figure 6 Virus titers of hearts in the infected mice on days 7
and 14 (n = 8 in each group). Control, normal mice treated with
normal saline solution; Myocarditis, infected mice treated with
normal saline solution; Carvedilol, infected mice treated
with carvedilol.
Figure 7 CVB-3 RNA abundance in the infected myocardium of
mice on days 7 and 14 (n = 8 in each group). Carvedilol slightly
reduced the CVB-3 RNA abundance compared to the myocarditis
group. nd, not detected. Control, normal mice treated with normal
saline solution; Myocarditis, infected mice treated with normal saline
solution; Carvedilol, infected mice treated with carvedilol.
Figure 8 The effects of carvedilol on cardiac phosphorylated CREB and CREB on days 7 and 14 (n = 8 in each group). a, phosphorylated
CREB (pCREB) on day 7; b, phosphorylated CREB (pCREB) on day 14; c, CREB on day 7; d, CREB on day 14. *P<0.05 versus control; **P<0.05 versus
myocarditis. Control, normal mice treated with normal saline solution; Myocarditis, infected mice treated with normal saline solution; Carvedilol,
infected mice treated with carvedilol.
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cantly lesser in the carvedilol group compared with the
myocarditis group (P < 0.05; Figure 10a). On day 14, no
differences in the mRNA levels of the IL-6 and TNF-α
were found among the carvedilol group and myocarditis
group and normal control group (P > 0.05; Figure 10b).ELISA analysis of cytokines levels in the heart
On day 7, the levels of TNF-α and IL-6 were signifi-
cantly lower in the carvedilol group compared with the
myocarditis group (P < 0.05; Figure 11a), but carvedilol
had no effect on the MCP-1. On day 14, no differences
in the levels of the IL-6, TNF-α, and MCP-1 were found
among the carvedilol group and myocarditis group and
normal control group (P > 0.05; Figure 11b).Correlation between the expression of CREB, pCREB and
the levels of inflammatory cytokines
We used the Pearson’s correlation analysis method to as-
sess the relationship between the expression of CREB or
pCREB and the levels of inflammatory cytokines. Bivariate
correlations analysis fit a straight line to the significant
negative relationship between the expression of CREB or
pCREB and the levels of IL-6 (r = −0.553 and −0.578, re-
spectively; Figure 12) or TNF-α (r = −0.782 and −0.705,
respectively; Figure 12) on day 7. The expression of CREB
and pCREB was not correlated with the levels of MCP-1
mRNA (r = −0.265 and −0.463, respectively, P > 0.05).
Discussion
Two major findings were obtained in the present study.
First, the phosphorylation and expression of CREB were
Figure 9 Expression of cytokine mRNAs by Semi-Quantitative
PCR analysis in the myocardial tissues of mice on days 7 and
14 (n = 8 in each group). a, cytokine mRNAs on day 7; b, cytokine
mRNAs on day 14. Control, normal mice treated with normal saline
solution; Myocarditis, infected mice treated with normal saline
solution; Carvedilol, infected mice treated with carvedilol. *P<0.05
versus control; **P<0.05 versus myocarditis.
Figure 10 Expression of cytokine mRNAs by Quantitative PCR
analysis in the myocardial tissues of mice on days 7 and 14 (n = 8
in each group). a, cytokine mRNAs on day 7; b, cytokine mRNAs on
day 14. Control, normal mice treated with normal saline solution;
Myocarditis, infected mice treated with normal saline solution;
Carvedilol, infected mice treated with carvedilol. *P<0.05 versus
control; **P<0.05 versus myocarditis.
Li-Sha et al. BMC Cardiovascular Disorders 2013, 13:100 Page 10 of 14
http://www.biomedcentral.com/1471-2261/13/100decreased with concomitant increase of proinflammatory
cytokines in murine coxsackievirus-induced acute viral
myocarditis. The levels of IL-6 and TNF-α were correlated
with the expression of CREB or pCREB. This finding indi-
cates that the cardiac transcriptional factor CREB may be
involved in the pathophysiology of viral myocarditis. Sec-
ond, carvedilol increased cardiac CREB expression and
phosphorylation and decreased the plasma catecholamine
levels and the production of IL-6 and TNF-α with amelior-
ation of acute viral myocarditis. These results show that by
blocking catecholamine stimulation and increasing the car-
diac CREB expression and phosphorylation, carvedilolexerts some of its beneficial effects by suppressing the IL-6
and TNF-α. To the best of our knowledge, this is the first
study to investigate the effects of carvedilol on cardiac
CREB expression and phosphorylation in viral myocarditis.
CREB expression and phosphorylation in viral myocarditis
It is well-known that stimulation of β-adrenergic recep-
tor by catecholamines results in the elevation in the
intracellular concentration of the second messenger
cAMP [39]. Increased production of cAMP leads to acti-
vation of protein kinase A, which in turn causes phos-
phorylation/activation of CREB and subsequent gene
expression through CRE-mediated transcription [20].
Recent studies have indicated an important role of CREB
in the development of the cardiovascular diseases such
as heart failure, atherosclerosis, restenosis, and reperfu-
sion injury [21-29]. Moreover, emerging evidence has re-
vealed specific functions of CREB in immune responses,
including regulating NF-kB activation [40,41], inducing
Figure 11 Cytokine levels measured by ELISA analysis in the
myocardial tissues of mice on days 7 and 14 (n = 8 in each
group). a, level of cytokines on day 7; b, level of cytokines on day
14. Control, normal mice treated with normal saline solution;
Myocarditis, infected mice treated with normal saline solution;
Carvedilol, infected mice treated with carvedilol. *P<0.05 versus
control; **P<0.05 versus myocarditis.
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eration, survival, and regulation of T and B lymphocytes
[40,42,43]. It has been suggested that CREB is involved in
suppression of cytokine gene expression, including IL-6
and TNF-α, and promotes anti-inflammatory immune
responses [18,40,41,44-48]. In the present study, CREB
expression and phosphorylation were decreased with
concomitant increase of IL-6 and TNF-α. The levels of IL-
6 and TNF-α were correlated with the expression of CREB
or pCREB. It has been suggested that cytokines exert an
important role in the pathophysiology of viral myocarditis
[49-53]. IL-6 and TNF-α are both involved in the patho-
genesis of myocarditis and may induce advanced cardiac
dysfunction [50,52,53]. CREB may thus play an important
role in the pathogenesis of viral myocarditis. The reduc-
tion in CREB expression and phosphorylation in viral
myocarditis may be caused by several mechanisms. First,prolonged explosure to elevated catecholamine levels lead
to the desensitization of cardiac β-adrenergic receptors
signaling that limit cAMP production and reduce the ex-
pression and phosphorylation of CREB [11,54]. Previous
studies have demonstrated that cardiac CREB alteration
was associated with catecholamines stimulation time.22,54
CREB mRNA was increased after short-term (30 min)
stimulation with forskolin, an activator of cAMP [55],
while prolonged β-adrenergic stimulation in rats by a 4-
day infusion of isoproterenol decreased CREB mRNA
[22]. Second, a direct proteolytic cleavage of CREB by vi-
ruses may lead to the reduction in CREB. A few studies
have demonstrated that infection of susceptible cells with
members of the picornavirus family results in the rapid in-
hibition of host cell RNA synthesis [56-59]. Yalamanchili
et al. found that CREB and pCREB were specifically
cleaved by the poliovirus-encoded protease 3C pro both
in vitro and in virus-infected cells [60]. Therefore, CVB3
may directly cleave the CREB protein and result in the re-
duction of CREB.
Effects of Carvedilol on CREB expression and
phosphorylation in viral myocarditis
In this study, treatment with carvedilol decreased the
plasma levels of noradrenaline and increased the expres-
sion and phosphorylation of cardiac CREB. As mentioned
previously [11,54], elevated circulating catecholamines
may lead to decreased levels and functional activity of
cardiac β-adrenergic receptors and thus to marked desen-
sitization of the heart to inotropic β-adrenergic stimula-
tion. Treatment with carvedilol may normalize or remodel
signaling through the cardiac β-adrenergic system by re-
ducing desensitization, enhancing catecholamine sensitiv-
ity, and raising levels of β-adrenergic receptors [11,32,54].
Thus, decreased β-adrenergic stimulation by carvedilol
treatment may contribute to the increase in the expression
and phosphorylation of CREB. In agreement with previous
studies from our and other laboratories [30,31,33-35], we
found that carvedilol improved the survival of mice and
reduced myocardial inflammation and necrosis in murine
viral myocarditis by downregulating the production of IL-
6 and TNF-α. In this study, we found that the levels of IL-
6 and TNF-α was negatively correlated with the cardiac
CREB and pCREB. Moreover, previous studies have found
that CREB was involved in suppression of IL-6 and TNF-α
gene expression in other systems [18,40,41,46-48]. There-
fore, the reduction in the production of IL-6 and TNF-α
may be associated with the increase of CREB in the study.
Recent reports have also emphasized the other cellular
mechanisms in murine myocarditis [61-65]. After viral
entry acute injury of the myocytes induced by virus rep-
lication leads to myocyte necrosis, exposure of intracel-
lular antigens (e.g., cardiacmyosin), and activation of the
host’s immune system, which is characterized by the
Figure 12 Correlation between pCREB, CREB and inflammatory cytokines. Pearson's correlation analysis demonstrated that the protein
expression of pCREB and CREB was negatively correlated with the expression of IL-6 and TNF-α mRNA on day 7, but not correlated with the
expression of MCP-1 mRNA. a, Correlation between pCREB protein and IL-6 mRNA; b, Correlation between pCREB protein and TNF-αmRNA;
c, Correlation between pCREB protein and MCP-1 mRNA; d, Correlation between CREB protein and IL-6 mRNA; e, Correlation between CREB
protein and TNF-αmRNA; f, Correlation between CREB protein and MCP-1 mRNA. *P<0.05; **P<0.01.
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http://www.biomedcentral.com/1471-2261/13/100invasion of natural killer cells and macrophages followed
by T lymphocytes. After the acute phase of virus-
induced injury, the second phase is characterized by
(auto)immune reactions. This subacute phase is defined
by activated virus-specificT lymphocytes, which may tar-
get the host’s organs by molecular mimicry. Kania and
Shi et al. reported that toll-like receptors transmit a cas-
cade of signals to activate nuclear transcription factors,
such as nuclear factor κB, and lead to inflammatory
cytokine production and immune activation. Cytokine
activation (IL-6 and TNF-α) and antibodies to viral and
cardiac proteins may aggravate cardiac damage and
cause impairment of the contractile function.
Study limitations
The survival rate, HW/BW ratio and myocardial histo-
pathology of infected mice were studied in the present
study. However, cardiac function and volume were not
studied by echocardiographic examination. In addition, al-
though the cardiac transcriptional factor CREB appears to
be involved in the pathophysiology of viral myocarditis,
further research to reveal signaling pathways or collaborat-
ing proteins that are selectively involved in its proinflam-
matory or its anti-inflammatory functions is needed.
Conclusions
The expression and phosphorylation of CREB were de-
creased in murine coxsackievirus-induced acute viral
myocarditis. Administration of carvedilol causes an in-
crease in the expression and phosphorylation of CREB to-
gether with the reduction in the production of IL-6 and
TNF-α. The levels of IL-6 and TNF-α were correlated with
the expression of CREB or pCREB. Although the cardiac
transcriptional factor CREB appears to be involved in the
pathophysiology of viral myocarditis, further research to
reveal signaling pathways or collaborating proteins that
are selectively involved in its proinflammatory or its anti-
inflammatory functions is needed.
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